Document is current
Any future updates will be listed below
-
Authors
Lee, Dawn http://orcid.org/0000-0003-4027-8456
McCarthy, Grant http://orcid.org/0000-0001-8292-8598
Saeed, Omar http://orcid.org/0000-0002-3600-3591
Allen, Rachel http://orcid.org/0000-0002-9371-3493
Malottki, Kinga http://orcid.org/0000-0003-2285-3584
Chandler, Fleur http://orcid.org/0000-0003-0514-5279
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Accepted: 26 September 2022
First Online: 31 October 2022
Change Date: 20 November 2022
Change Type: Update
Change Details: The presentation of bulletpoints was incorrect in the original version of this article.
Declarations
:
: This study was funded by Sanofi.
: Grant McCarthy is employed by Lumanity and Dawn Lee was employed by Lumanity at the time of writing. Lumanity was reimbursed by Sanofi as a consultancy for time spent developing this article. Rachel Allen, Fleur Chandler, Kinga Malottki and Omar Saeed are employees of Sanofi, the manufacturer of caplacizumab and may hold shares and/or stock options in the company. Omar Saeed was previously employed by Shire, the (previous) manufacturer of teduglutide.
: Not applicable.
: Not applicable.
: Not applicable.
: All data were taken from publicly available materials that are referenced in the article.
: Calculations may be shared on request.
: All authors were involved in the design and execution of the analysis, interpretation of the results, and the drafting and revision of the manuscript, and provided final approval of the version to be published. All authors vouch for the accuracy of the content included in the full article.
